Abstract: An ultrasound contrast agent (Optison/sup /spl reg//) was use with focused ultrasound to target the vasculature directly and produce localized lesions in the brain at low power levels. Also, ...
The International Contrast Ultrasound Society (ICUS) today announced a handy new chart that may be used to guide coding and payment for contrast enhanced ultrasound (CEUS) for cardiac and non-cardiac ...
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a ...
A look back at the FDA submissions and regulatory decisions in the pediatric health care space from May 2025. Another month has come and gone, and with it, several FDA approvals and regulatory updates ...
Expanding the approval to pediatric patients is expected to improve the diagnostic accuracy of echocardiograms. The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A ...
GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands ...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes SoFi Technologies, Inc. (NASDAQ:SOFI), adding that the stock goes to “new highs.” To support his view, the company reported quarterly ...
The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound ...
"In some pediatric patients, standard echocardiography cannot produce sufficiently clear images of the heart, potentially hindering cardiologists' ability to accurately diagnose underlying conditions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results